Streetbeat News

Products Services

HPE

JPM

KRE

ORCL

TLT

XLE

XLF

Wall Street experienced a downturn as investors awaited the Trump-Harris debate. Energy and financial sectors underperformed, with oil prices dropping due to OPEC's revised demand forecasts. Regulatory changes by the Federal Reserve affected bank stocks, with JPMorgan Chase falling 7%. The SPDR Regional Banking ETF also declined. Meanwhile, Oracle saw a 12% rise due to strong earnings, while Hewlett Packard Enterprise fell over 7% after announcing a public offering.

Portfolio Pulse from Piero Cingari

September 10, 2024 | 5:39 pm

AMD

COMM

FIVN

MARA

MSTR

NVDA

PLTR

SMCI

TSM

The article highlights unusual options activity for several IT stocks, indicating potential trading opportunities. Notable mentions include NVDA, PLTR, MU, AMD, SMCI, MSTR, MARA, TSM, COMM, and FIVN, with varying bullish and bearish sentiments.

Portfolio Pulse from Benzinga Insights

September 10, 2024 | 5:35 pm

COP

PSX

WEX

WEX has expanded its DriverDash app to thousands of Phillips 66, Conoco, and 76 locations across the U.S., enhancing its service offerings and potentially increasing its user base.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:33 pm

ALT

Altimmune shares rose following the presentation of positive data from its Phase 2 study on pemvidutide, targeting overweight and obese individuals.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:31 pm

AMZN

NVDA

ORCL

Amazon and Oracle have formed a new partnership to enhance cloud services, which has led BofA Securities analyst Justin Post to maintain a Buy rating on Amazon with a price target of $210. The partnership aims to integrate Oracle's databases with AWS applications, offering seamless data access and administration. This collaboration is expected to unlock significant growth opportunities in cloud infrastructure and applications. Additionally, AWS CEO Matt Garman expressed optimism about AI demand and AWS's infrastructure. Amazon's stock is currently up 2.54%.

Portfolio Pulse from Anusuya Lahiri

September 10, 2024 | 5:23 pm

PLTR

Palantir Technologies has teased a new development with a cryptic post on X, hinting at something significant 'coming soon'. This has sparked curiosity and speculation among investors and analysts.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:19 pm

JNJ

PTGX

TAK

Truist Securities initiated coverage on Protagonist Therapeutics (PTGX) with a Buy rating and a $60 price target, highlighting its promising investigational candidates rusfertide and JNJ-2113. These assets target a market exceeding $10 billion, with significant potential in blood cancer and psoriasis treatments. Partnerships with Takeda and Johnson & Johnson bolster PTGX's prospects.

Portfolio Pulse from Vandana Singh

September 10, 2024 | 5:17 pm

SMMT

Summit Therapeutics shares are experiencing an increase in trading value following the company's announcement of data presentation on Ivonescimab monotherapy over the weekend.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:14 pm

ALT

Altimmune has corrected its previous release regarding the reduction of visceral and subcutaneous adipose tissue in a Phase 2 study. The visceral adipose tissue reduction at week 48 is now reported as 28.3%, up from 25.6%, while subcutaneous adipose tissue reduction is revised to 19.5% from 20.1%.

Portfolio Pulse from Benzinga Newsdesk

September 10, 2024 | 5:14 pm

IVW

IWF

NVDA

TSM

Nvidia faces investor concerns over delays in its Blackwell chip rollout, impacting its stock price. Despite a 15% drop, Nvidia anticipates significant revenue from Blackwell in the fiscal fourth quarter. Analysts highlight the delay as a concern, but some remain optimistic due to Nvidia's AI ambitions and supplier growth.

Portfolio Pulse from Anusuya Lahiri

September 10, 2024 | 5:12 pm